Recent Advances in Cervical Cancer Treatment

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.

Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.

Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.

An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.

Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.

Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.

Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.

Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.